Capricor Therapeutics 的 SARS-CoV-2 StealthX 疫苗被选入 COVID-19 Project NextGen，份额增加了 7%。 Capricor Therapeutics' StealthX vaccine for SARS-CoV-2 was selected for COVID-19 Project NextGen, increasing shares by 7%.
Capricor Therapeutics 的基于 StealthX 外泌体的多价疫苗被美国卫生与公众服务部的 NextGen 项目选中，该项目旨在推进针对 COVID-19 的新型创新疫苗研发管线，该公司的股价上涨了 7%。 Capricor Therapeutics' share price rose by 7% after the company's StealthX exosome-based multivalent vaccine was selected for Project NextGen, a U.S. Department of Health and Human Services initiative aimed at advancing a pipeline of new, innovative vaccines for COVID-19. 该疫苗结合了 S 蛋白和 N 蛋白，旨在针对 SARS-CoV-2 提供更广泛、更持久的免疫力。 The vaccine, which combines the S protein and the N protein, aims to offer broader and longer-lasting immunity against SARS-CoV-2. 美国国立卫生研究院将监督该疫苗的一期临床研究，但需获得监管部门的批准，此次合作旨在开发可扩展到其他传染病的下一代疫苗平台。 The National Institutes of Health will oversee a Phase 1 clinical study of the vaccine, subject to regulatory approval, and the collaboration seeks to develop next-generation vaccine platforms that could be extended to other infectious diseases.